The robust transcriptional regulation provided by T-ATF targeting VEGF-A indicates that replacing the VP64 domain with a repressor, such as the KRAB domain, would make it a potential therapeutic for neovascular glaucoma and wet AMD. The gene discussed is VEGFA; the disease is wet macular degeneration.